Radotinib

Radotinib, also known by the brand name Supect, is a tyrosine kinase inhibitor used in the treatment of chronic myeloid leukemia (CML). Specifically, it is approved for use in patients with chronic phase CML who are resistant or intolerant to prior tyrosine kinase inhibitor therapy, including imatinib.

Radotinib functions by inhibiting the BCR-ABL tyrosine kinase, an abnormal protein that results from the Philadelphia chromosome translocation and drives the uncontrolled proliferation of leukemic cells in CML. By blocking the activity of BCR-ABL, radotinib helps to suppress the growth and spread of CML cells.

Radotinib is administered orally. Common side effects associated with its use include myelosuppression (decreased blood cell counts), gastrointestinal disturbances (nausea, vomiting, diarrhea), skin rash, and edema. As with other tyrosine kinase inhibitors, monitoring of blood counts and liver function is required during treatment with radotinib. It is crucial to discuss potential risks and benefits with a healthcare professional before starting treatment.